Skip to main content
OpenTrials
Completed

NCT Number: NCT05341687

Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.

Mortality of patients with COVID-19 associated acute respiratory distress syndrome (CARDS) treated with veno-venous extra-corporal membrane oxygenation (vv-ECMO) is increasing over time since the beginning of the COVID-19 pandemic. The objectives were to retrospectively describe over the first ten days after vv-ECMO implantation, the ventilatory management of CARDS and to assess the impact of static respiratory system compliance (CRS) on the first day of vv-ECMO on 180-day mortality.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ARDS Acute Lung Injury Extracorporeal Membrane Oxygenation Lung Diseases Lung Injury Mechanical Ventilation Pressure High Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Nancy

Nancy, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with ARDS secondary to COVID-19 pneumonia requiring ECMO-VV support, hospitalized in the intensive care units of the CHRU of Nancy, Marseille or Bordeaux between 01/03/2020 and 31/12/2021.
  • Age > 18 years old

Exclusion criteria

  • Respiratory parameters not available on ten first day of VV ECMO implantation.
  • Patient refusal to participate in the study

Treatment and study plan

No applicable

Other

No applicable

Primary outcomes

  1. Vital status (dead or alive)

    Time frame: Days, 10.

    according to compliance during the first ten days of VV ECMO implantation

Secondary outcomes

  1. Evolution of driving pressure

    Time frame: Days, 10

    after VV-ECMO implantation

  2. Evolution of tidal volume

    Time frame: Days, 10

    after VV-ECMO implantation

  3. Evolution of PEEP

    Time frame: days, 10

    after VV-ECMO implantation

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in Patients With COVID-19 Associated Acute Respiratory Distress Syndrome (CARDS)

Acronym: COMPLIECMO

Important dates

Study start
2020
Primary completion
2021
Study completion
2023
First posted
Apr 22, 2022
Registry last updated
Jul 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.